Manufacturer
ASTRAZENECA AB
Contents
Ticagrelor
Indication
60 mg: Co-administered w/ acetylsalicylic acid (ASA) for prevention of atherothrombotic events in adult patient w/ history of MI (occurred at least 1 yr ago) & high risk of developing atherothrombotic event. 90 mg: Co-administered w/ ASA for prevention of atherothrombotic events in adult patients w/ acute coronary syndromes (unstable angina, non-ST elevation MI, ST elevation MI); including patients managed medically, w/ percutaneous coronary intervention or CABG.
Instruction
May be taken with or without food: For patients w/ swallowing difficulties, crush tab to a fine powd & mix in ½ glass of water & drink immediately. Rinse glass w/ another ½ glass of water & drink. The mixt may be administered via a nasogastric tube (CH8 or greater). Flush tube w/ water after administration.
Drug interaction
Increased Cmax & AUC w/ strong CYP3A4 inhibitors eg, ketoconazole; moderate CYP3A4 inhibitors eg, diltiazem; cyclosporine. Decreased Cmax & AUC w/ CYP3A4 inducers eg, rifampicin. Increased Cmax & AUC of simvastatin, atorvastatin, digoxin. Increased exposure to CYP3A4 substrates w/ narrow therapeutic index eg, cisapride, ergot alkaloids. Increased risk of bleeding w/ SSRIs.
Malaysia
